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It has been suggested that the presence of immunoglobulin and complement receptors on rectal epithelium may facilitate
the entry of HIV complexed to nonneutralizing antibody. We tested this hypothesis using simian immunodeficiency virus (SIV)
infection of rhesus macaques. First, in a pilot study, a nonneutralizing IgG fraction of macaque anti-SIV gp120 was shown to
enhance the immunogenicity of SIV envelope following rectal immunization. The same antibody was then mixed with a
subinfectious dose of SIV and the occurrence of rectal infection was compared with virus alone. Animals were not infected
overtly and were rechallenged with a 10-fold higher dose of virus with and without addition of antibody. There was no
evidence of antibody-mediated infection, since equal numbers of macaques became infected, regardless of the presence of
antibody. In addition, the application of immune complexes did not alter significantly the subsequent virus load or the immune
responses generated. In seronegative animals, in which virus and proviral DNA were undetectable in PBMC and tissues,
SIV-specific T-cell responses and antibody-secreting cells were found in systemic and gut-associated sites. Our results show
that nonneutralizing antibody neither facilitated nor enhanced rectal infection with SIV, in the small number of animals used,
despite the consistent trend for this antibody to enhance antibody responses to gp120 following rectal immunization with
immune-complexed antigen. However, mucosal exposure to subinfectious doses of virus primed both systemic and local
immunity, regardless of addition of nonneutralizing antibody. © 2001 Academic PressINTRODUCTION
Human immunodeficiency virus (HIV) is transmitted
primarily via mucosal surfaces and this can be modeled
in macaques using simian immunodeficiency virus (SIV)
(Cranage et al., 1992). To develop rational vaccine and
therapeutic strategies, it is important to understand how
the virus is transmitted across the intact mucosal surface
and what local immune responses are generated, as
these may modulate subsequent spread of the virus and
confer resistance to subsequent exposure. Mucosal
transmission may involve direct infection of lymphoid
cells, perhaps through small breaks in the mucosa. An-
other possibility is a non-CD4-dependent entry mecha-
nism into epithelial cells. Fcg2 and Fcg3 receptors have
been identified on human and simian rectal epithelial
cells (Hussain et al., 1991; Hussain and Lehner, 1995),
raising the possibility that SIV or HIV may cross the
epithelial barrier by means of virus–IgG antibody com-
plexes binding to these receptors. In natural infection,
the individual may be exposed to virus that is complexed
to nonneutralizing antibody, either derived from the trans-
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527mitting partner (Witkin et al., 1980) or arising in the
recipient as a result of previous low-dose exposure to
virus. Furthermore, in response to mucosal vaccines,
immunized subjects may develop antibodies at the virus
portal of entry and, if the antibodies are nonneutralizing,
they may facilitate virus entry. In addition, it was previ-
ously demonstrated in vitro, that significant enhance-
ment of virus replication occurs in cells infected with
HIV-1 in the presence of subneutralizing concentrations
of serum antibodies (Takeda et al., 1988; Takeda and
Ennis, 1990). However, enhanced antibody-mediated HIV
or SIV replication has not yet been demonstrated in vivo.
Mucosal exposure to virus may result in a self-limiting
or occult infection, giving rise to selective immune re-
sponses, as indicated by studies in humans and mon-
keys, and has in some cases been associated with
protection from subsequent exposure. A significant num-
ber of commercial sex workers exposed to HIV-1 (Row-
land-Jones et al., 1995, 1998) or who have HIV-infected
partners (Langlade-Demyen et al., 1994; Clerici, 1992)
appear to resist infection. HIV-specific T-helper and cy-
totoxic T lymphocytes (CTL) (Rowland-Jones et al., 1993,
1995; Langlade-Demyen et al., 1994; Shearer and Clerici,
1996), mucosal HIV-1-specific IgA antibody responses
1(Mazzoli et al., 1997; Kaul et al., 1999), and CD8 antiviral
activity (Stranford et al., 1999) were detected in subjects
0042-6822/01 $35.00
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528 POLYANSKAYA ET AL.who were not infected, despite being exposed to HIV.
Similar observations were reported in the SIV model
following inoculation of low doses of pathogenic virus by
the intrarectal (Pauza et al., 1993; Clerici et al., 1994;
Trivedi et al., 1996; Murphey-Corb et al., 1999), oral (Van
Rompay et al., 1998), intravaginal (McChesney et al.,
1998), or intravenous (Dittmer et al., 1995) routes. There
are, however, only limited data on the stimulation of local
T cells and antibody-secreting cells (ASC) following sub-
infectious exposure.
In the study described here, we sought to establish
whether rectal infectivity in macaques can be facilitated
(infection with subinfectious dose) or enhanced (higher
virus loads upon infection) by nonneutralizing anti-SIV
gp120 IgG antibodies. Furthermore, in this study we
examined gut-associated and systemic ASC and T-cell
function in virus-exposed animals that remained unin-
fected by the criteria of virus isolation, proviral DNA
detection in blood and tissue mononuclear cells (MNC),
and detection of viral RNA in plasma.
RESULTS
Outcome of immunization of macaques with antibody-
complexed gp120 or gp120 alone
We compared the immunogenicity of affinity-purified
SIV gp120 given alone or as immune complexes with a
FIG. 1. Serum and rectal antibody responses in macaques immunized
show IgG titers and empty bars show IgA titers.nonneutralizing IgG fraction of a serum pool from ma-
caques immunized with gp120. Two macaques (50 and51) were immunized intrarectally, first with immune com-
plexes in antibody excess, then in equilibrium, followed
by complexes in antigen excess and boosted by the
intramuscular (im) route at about monthly intervals. An-
other macaque (24) received gp120 alone, following the
same schedule, and two animals (86 and 87) were im-
munized im once with gp120 alone. Intrarectal inocula-
tions were given in the absence of adjuvant, although
alum was used in the im administration. Secretory and
serum IgA and IgG antibody responses to the complexed
gp120 were enhanced as compared with gp120 alone
after the three rectal inoculations (Fig. 1). A T-cell-prolif-
erative response was detected in only one animal (50)
that received the gp120–IgG complex [stimulation index
(SI) 5 3.3]. A single intramuscular boost stimulated a
further increase in the antibody levels in the gp120–IgG
complex immunized animals; T-cell-proliferative re-
sponses were detected in both animals (SI 5 3.1 for
animal 50, and 27.7 for animal 51). In contrast, the ma-
caque immunized with gp120 alone showed no increase
in rectal or serum antibodies, although the T-cell-prolif-
erative response reached a significant level (SI 5 4.6).
In vivo infectivity titer of SIVmac220
To test whether anti-gp120 IgG antibodies could facil-
itate or enhance SIV infection in vivo, the titer of infec-
p120 anti-envelope IgG immune complexes or gp120 alone. Solid barstivity of the virus stock was determined by intrarectal
titration in eight macaques. Two of the two animals
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529LOCAL IMMUNITY AFTER LOW-DOSE MUCOSAL EXPOSURE TO SIVreceiving the highest dose of SIV (6000 TCID50), two of
wo receiving 1200 TCID50, and one of the two animals
receiving 240 TCID50 became infected (Table 1). Virus
as not isolated from the remaining two animals; they
lso failed to seroconvert and PCR analysis of PBMC
ailed to reveal proviral DNA (Table 1). Thus, within the
imitations of the titration, one median infectious dose
MID50) of SIVmac220 was found to be equivalent to 240
CID50 following intrarectal inoculation.
utcome of in vivo exposure to virus and immune-
complexed virus
Virus infectivity. Having determined that the dose of
virus required to infect 50% of animals by rectal inocu-
lation was 240 TCID50, another four macaques were
noculated rectally with 120 TCID50 alone and another
four animals received the same dose of SIV but com-
plexed to the nonneutralizing IgG antibodies. This “sub-
infectious” dose of SIV, either in the presence or in the
absence of antibody, failed to infect macaques. All ani-
mals remained negative for virus isolation and PCR, nor
did they develop serum or rectal antibodies or a T-cell-
T
Intrarectal Titration of SI
Animal
Inoculum
TCID50 Week 2 Wee
10T 6000 1 1
4T 6000 1 1 [
14T 1200 1 1
19T 1200 1 1
28S 240 1 1 [
25T 240 2 2 [
5T 48 2 2 [
18T 48 2 2 [
T
Cell-Associated and Plasma RNA Viral Loads After th
Inoculum Animal
Week 1 We
PBMCa Plasmab PBMCa
SIV-immune
complex
54T ,1.6 ,140 312.5
147T ,1.6 nt 3,509
V14 ,1.6 ,140 ,1.6
V2 ,1.6 ,140 ,1.6
SIV alone
73T ,1.6 ,140 ,1.6
70T ,1.6 1,800 2.5
51T ,1.6 ,140 ,1.6
60T ,1.6 ,140 140
a 6No. of SIV infected cells/10 PBMC.
b SIV RNA Eq/ml plasma; nt 5 not tested.proliferative response to SIV. The same animals were
rechallenged rectally at Week 17 with SIV–immune com-
plexes or SIV alone as previously, but using a 10-fold
higher concentration of SIV (1200 TCID50). By 2 weeks
after the second SIV challenge, two of four macaques in
each group had become overtly infected as indicated by
virus isolation (Table 2). As the number of infected ani-
mals in each group was the same, there was no evi-
dence that the nonneutralizing macaque anti-SIV gp120
IgG facilitated infection via the rectal mucosa. However,
the cell-associated virus loads were higher at Week 2 in
animals given the SIV–immune complexes, compared to
those receiving virus alone, which showed a higher load
at Week 4 (Table 2). This difference was not reflected in
the plasma RNA loads; indeed, the highest load was
detected in an animal infected with virus alone (70T) and
this was the only animal in which RNA was detected at
1 week after challenge.
To determine whether exposed, “uninfected” (EU) ani-
mals had local sequestration of challenge virus, various
lymphoid tissues (iliac, mesenteric, and axillary lymph
nodes; spleen; PBMC) were analyzed post mortem 22–44
20 in Rhesus Macaques
Virus isolation from PBMC [PCR]
Week 6 Week 8 Autopsy (week)
1 1 1 (13)
1 1 1 (13)
1 1 1 (10)
1 1 1 (10)
1 1 1 (9)
2 2 2 (9)
2 2 2 (10)
2 2 2 (10)
nd Rectal Inoculation of Macaques, with 1200 TCID50
Week 4 Week 8
mab PBMCa Plasmab PBMCa Plasmab
000 2.5 180,000 nt 440,000
000 5.5 380,000 nt 32,000
0 ,1.6 ,140 nt ,140
t ,1.6 ,140 nt ,140
0 ,1.6 nt nt ,140
0,000 140 510,000 nt 170,000
0 ,1.6 ,140 nt ,140
00 1,562 210,000 nt 24,000ABLE 1
Vmac2
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530 POLYANSKAYA ET AL.weeks after the second exposure to the virus. All tissues
were negative for virus isolation and for the presence of
provirus by PCR.
SIV-specific immune responses. All four infected ani-
mals seroconverted and serum antibody titers to whole
virus, gagp27, and gp140 were not enhanced by infection
with immune-complexed virus (Fig. 2). Thus, immune-
complexed SIV did not enhance systemic SIV-specific
antibody responses.
To determine whether rectal mucosal exposure to vi-
rus, in the presence and absence of specific IgG anti-
bodies, had stimulated local or systemic cellular immune
responses, cells from blood and tissues were analyzed
post mortem. In the exposed, uninfected animals, SIV
antigen-specific T-cell-proliferative responses were evi-
dent in the cells recovered from blood and lymphoid
FIG. 2. Anti-SIV serum antibody responses. First exposure (120
CID50) and second exposure (1200 TCID50) to virus alone (filled sym-
bols) or immune complexes (open symbols) are shown with arrows.
Serum antibody titers were determined by ELISA against the antigens
indicated.tissues (Table 3). Proliferation with stimulation indices
(SI) to p27 and gp120 between 2.6 and 10.2 was detected
i
min jejunal IEL (V14), jejunal LPL (51T), iliac lymph nodes
(73T and V2), mesenteric lymph nodes (51T, 73T, and V2),
axillary lymph nodes (51T, 73T, and V2), and blood (V2).
Infected animals failed to exhibit SIV-specific T-cell-pro-
liferative responses in the gut, iliac, and mesenteric
lymph nodes and spleen, although p27-driven prolifera-
tion was detected in axillary lymph nodes in one ma-
caque (147T) and in blood in the other (54T). Maximum
proliferative responses were stimulated with different
concentrations of antigen that varied between the tis-
sues (Table 3). Lamina propria lymphocytes from animal
73T and PBMC from animal 51T showed nonsignificant
proliferative values at single concentrations of antigen.
In contrast, MNC from axillary lymph nodes of animal 51T
were reactive at every concentration of gp120 tested (1,
5, 10 mg/ml) but with high replicate variability. Cells from
lood (n 5 12) and different tissues (gut, iliac, mesen-
eric, and axillary lymph nodes, and spleen; n 5 3) of
aive macaques were also assayed under the same
onditions. In no instance did the level of stimulation
each a value of 2.5.
In addition to lymphoproliferative responses, we ex-
mined CTL activity against autologous target cells ex-
ressing SIV antigens from recombinant vaccinia vi-
uses. Previous observations in our laboratory showed
hat cells from GALT frequently die in culture and, there-
ore, cells were analyzed directly for CTL effector activity.
evels of direct net SIV-specific CTL of 10% or greater
ere detectable at an effector-to-target ratio of 200:1 in
wo of four EU animals and two of three infected animals
Fig. 3). Systemic CTL were found in two EU animals (V2;
xillary lymph node and spleen, 73T; PBMC) and in one
nfected macaque (147T; spleen and PBMC). Local CTL
o SIV env were detected in one EU animal (73T; jejunal
EL) and to SIV nef in one infected animal (60T; iliac
ymph node). MNC from the spleen of the SIV-infected
nimal 147T maintained nef-specific killing at 25:1 and
nv-specific killing at 50:1.
Antibody-secreting cells within MNC from two EU ma-
aques (51T and 73T) and two infected macaques (60T
nd 70T) were analyzed by the ELISPOT assay (Fig. 4).
oth EU and infected animals demonstrated significant
requencies of SIV-specific IgG ASC in the rectum, iliac,
nd axillary lymph nodes, spleen, and PBMC. Surpris-
ngly, the IgA ASC were negligible.
Thus, rectal mucosal exposure to SIV, in the absence
f overt infection, primed both virus-specific cell-medi-
ted immune responses and antibody-secreting cell ac-
ivity detectable at systemic and mucosa-associated
ites.
DISCUSSION
Little is known about early events in rectal mucosal
nfection with HIV, despite the fact that this is a frequent
ode of virus transmission. The possibility of antibody-
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531LOCAL IMMUNITY AFTER LOW-DOSE MUCOSAL EXPOSURE TO SIVfacilitated uptake of virus via Fcg receptors was previ-
usly suggested by several in vitro studies (Homsy et al.,
989; Takeda and Ennis, 1990; Robinson et al., 1990). It
as shown that IgG antibodies engaging FcgR3, unlike
FcgR1, can enhance HIV infection of macrophages, inde-
pendently of CD4 (Trischmann et al., 1995). Immune-
complexed virus may also be taken up in vitro via com-
plement receptors if complement is available (Montefiori
et al., 1990; Boyer et al., 1991). Interestingly, FcgR3 may
associate with complement receptor type 3 (CR3) and
co-cap on the plasma membrane, suggesting that the
two receptors cooperate in mediating biological function
(Zhou et al., 1993).
The significance of antibody and/or complement me-
diated facilitation in enhancement of infection is difficult
to study in man, although this is a matter of obvious
concern in vaccine design. In FIV infection of cats, en-
hancement was previously seen following vaccination
(Siebelink et al., 1995; Osterhaus et al., 1996). In the SIV
model we observed increased infection in one study of
macaques immunized with SIVgp120 and gag p27 follow-
ing rectal inoculation of the animals with a low dose of
virus (Cranage et al., unpublished data), suggesting the
ossibility of antibody-facilitated enhancement of infec-
ion.
Although only a small number of animals were used in
he pilot immunogenicity experiment, there was a con-
istent trend for rectally administered IgG immune com-
lexes of SIV gp120 to elicit higher titers of secretory and
erum antibodies compared to titers in animals given
T
SIV-Stimulated Proliferation of
Animal Exposed to Status Antigen
Maximum
IEL LPL
V2 SIV EU p27 nt 1.1
gp120 nt 1.2
73T SIV EU p27 1.8 5.3
gp120 1.0 1.0
51T SIV-ICa EUb p27 nt 3.2 (5)
gp120 nt 5.0 (5)
V14 SIV-IC EU p27 2.6 (2) 1.5
gp120 1.5 1.5
147T SIV-IC Infected p27 1.0 1.1
gp120 1.0 1.3
54T SIV-IC Infected p27 1.0 1.0
gp120 2.3 1.0
Note. Significant (P , 0.05) stimulation indices $ 2.5 are shown in
cultures. nt, not tested.
a IC, immune complex.
b EU, exposed, uninfected.p120 alone, either intrarectally or intramuscularly. This
uggests that the presence of Fcg and complement re-ceptors expressed by rectal epithelial cells (Hussain et
al., 1991; Hussain and Lehner, 1995) may have facilitated
antigen uptake. Alternatively, immune complexes may
have bound directly to macrophages, thus leading to
enhanced immune presentation.
A marked difference was found between the enhanced
immunogenicity of immune complexes, consisting of SIV
antigens and corresponding IgG antibodies, and the lack
of any effect of these antibodies on the infectivity or
immunogenicity of live SIV. The failure of the nonneutral-
izing anti-SIV gp120 IgG either to facilitate or to enhance
infection with SIV has several possible explanations.
First, complexed virus may not be taken up any more
efficiently than virus alone. Second, the antibody used
recognized native gp120, since it bound to the surface of
SIV-infected cells (data not shown). Such binding has
been shown to be a surrogate for virion binding (Satten-
tau and Moore, 1995). However, although the antigen:
antibody ratio was carefully worked out, we were unable
to do a similar titration for the virus:antibody ratio and we
used the ratios calculated for the antigen which may not
have been optimal for the virus. Third, antibodies can
neutralize or enhance HIV-1 infection, depending on the
phenotype of the virus used and/or the cell substrates
used in the production of the challenge virus (Schutten et
al., 1994; Osterhaus et al., 1996). In our study with SIV, the
virus was derived ex vivo without being cultured on cell
lines and, therefore, should have been close to a biolog-
ically relevant phenotype. Splenocyte-derived virus, how-
ever, may not represent a naturally transmitted pheno-
from SIV-Exposed Macaques
tion index (optimal antigen concentration mg/ml) in MNC from:
ac lymph
node
Mesenteric
lymph node
Axillary
lymph node Spleen
Peripheral
blood
.6 (8) 3.4 (4) 5.9 (8) 2.2 10.2 (1)
.5 (0.5) 1.8 3.5 (0.5) 2.1 8.0 (1)
.8 (8) 5.6 (1) 4.4 (1) 2.0 nt
.8 (2) 5.6 (4) 2.3 1.3 nt
.4 4.3 (10) 2.7 (10) 2.1 2.3
.6 3.9 (5) 3.9 1.4 3.4
.2 1.9 1.5 1.5 1.3
.1 1.7 1.5 1.9 1.1
.5 1.0 3.3 (2) 1.2 1.2
.4 1.6 1.4 1.6 1.5
.0 1.5 1.6 1.4 5.7 (8)
.2 1.4 1.4 1.0 1.7
the other SI . 2.5 showed considerable variations between triplicateABLE 3
MNC
stimula
Ili
3
2
6
5
1
1
1
1
1
1
2
1
bold;type. Finally, as only one type of antibody was used, we
cannot be confident that other antibodies directed to
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532 POLYANSKAYA ET AL.enhancing regions, such as were described for gp41
(Robinson et al., 1990), might not have yielded enhance-
ent.
We believe this to be the first prospective attempt to
tudy antibody-mediated facilitation of rectal mucosal
nfection in vivo using the SIV model and, with the above-
oted caveats, the failure to observe an effect is encour-
ging from the standpoint of vaccine development.
Our study also showed priming of both T- and B-cell
esponses following mucosal exposure to low doses of
irus, in the absence of overt infection. In the macaques
emaining seronegative the T-cell-proliferative re-
FIG. 3. SIV-specific CTL in mononuclear cells from tissues. All values
show net killing corrected for nonspecific antivaccinia virus activity at
an effector:target ratio of 200:1. Solid bars show killing of cells from
exposed, uninfected animals. Empty bars represent overtly infected
animals. Results are shown for gag (g), nef (n), and env (e) net-specific
release for each animal in the same order: g, n, e. The symbols for each
antigen appear above bars where net-specific killing is $10%.ponses were detected predominantly in the gut-associ-
ted iliac and axillary lymph nodes but not in the spleenor PBMC. This is consistent with the mucosal immune
responses found after local immunization, as compared
with systemic immunization (Lehner et al., 1994). Others
eported systemic T-cell responses in macaques that
ere transiently infected but which remained seronega-
ive (Salvato et al., 1994; Trivedi et al., 1996; McChesney
t al., 1998). In one study (Clerici et al., 1994), SIV-specific
esponses were detected in the circulation of macaques
hat were exposed to low doses of pathogenic virus but
ere apparently uninfected. More recently, Murphy-Corb
t al. (1999) reported the generation of CTL responses
etectable in the circulation and the jejunal lamina pro-
ria following colonic inoculation of macaques with SIV,
esulting in either transient or silent infection. In our
tudy, SIV-specific proliferative responses may have
risen from direct exposure to the inoculum (although
his contained only approximately 0.5 ng p27) or may
ave resulted from limited transient infection, despite the
act that no evidence was obtained of local sequestration
f virus. Surprisingly, we demonstrated low levels of
irect CTL activity in exposed uninfected macaques,
ncluding envelope-specific activity in jejunal intraepithe-
ial lymphocytes in one animal. This finding further sup-
orts the notion that limited viral replication may have
ccurred, since in one animal a CTL response to nef, a
onstructural protein, was detected. It is unclear how a
irect effector activity is maintained in the absence of a
ersisting viral infection and experiments are now in
rogress to analyze the generation of this activity using a
pecific CTL epitope marker.
As well as T-cell immune priming, low-dose exposure
o SIV was found to generate SIV-specific IgG antibody-
ecreting cells detectable in the rectum, iliac and axillary
ymph nodes, spleen, and PBMC. This extends and, in
he case of overtly infected animals, confirms the previ-
us observation in SIV-infected macaques (Bergmeier et
al., 1998). In both studies exposure to or infection with
SIV appeared to stimulate IgG-specific ASC. This finding
is of particular interest, given the recent observations
that SIV-specific IgG may be able to protect from muco-
sal infection (Baba et al., 2000; Mascola et al., 2000). The
apparent absence of IgA-specific ASC in tissues from
infected animals was surprising, given that such cells
were previously detected in our other studies (Bergmeier
et al., 1998; Polyanskaya et al., unpublished data). How-
ever, in the present study, tissues were frozen prior to
analysis and this may have reduced the sensitivity of the
assay.
The significance of immune responses induced by
low-dose exposure in protection against subsequent
challenge is yet to be fully resolved. In one study, re-
peated low-dose intravenous exposure of macaques to
SIV induced boostable SIV-specific proliferative T-cell
responses, although the animals were not protected
against subsequent intravenous challenge with a higher
dose of virus (Dittmer et al., 1995). Likewise, we were
s are s
533LOCAL IMMUNITY AFTER LOW-DOSE MUCOSAL EXPOSURE TO SIVable to infect animals that had failed to be infected in an
intrarectal titration when they were reexposed to a
higher dose of virus (Cranage et al., 1997 and this study).
In contrast, in other studies, protection against rectal
mucosal challenge was associated with T-cell re-
FIG. 4. Tissue distribution of SIV-specific antibody-secreting cells (A
tissues indicated. In each panel the left-hand side graphs show result
show results from overtly infected macaques (60T, 70T). ASC frequencie
shaded bars). Data are presented as means 6 SEM; nd 5 not done.sponses generated following both intravenous low-dose
exposure (Clerici et al., 1994; Putkonen et al., 1997) andintrarectal exposure (Trivedi et al., 1996; Murphey-Corb
et al., 1999). Indeed, in the latter study, protection corre-
lated with the presence of envelope-specific CTL in the
lamina propria. Protection was previously shown to be
associated with the generation of CD8-suppressor fac-
C were enumerated by ELISPOT assay in mononuclear cells from the
exposed, uninfected macaques (73T, 51T) and right-hand side graphs
hown for SIV p27 (open bars), SIV gp120 (solid bars), and KLH (control,SC). AS
s fromtors, b-chemokines, and SIV-specific ASC following im-
munization with p27 and gp120 by subcutaneous injec-
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534 POLYANSKAYA ET AL.tion in the region of the internal and external iliac lymph
nodes (Lehner et al., 1996; Bergmeier et al., 1998). Gut-
associated lymphoid tissue is a primary site for virus
replication following infection with SIV, even when ad-
ministered intravenously (Veazey et al., 1998). Although
infection with virulent virus is associated with a rapid
depletion of CD41 cells in GALT, infection with attenu-
ted virus induces protection against subsequent rectal
hallenge and induces SIV-specific immune responses
etectable in lymphoid tissue associated with the virus
ortal of entry (Cranage et al., 1997). These observations
suggest that local mucosal and regional lymph node
immune responses contribute to protection against rec-
tal challenge, as previously discussed (Lehner et al.,
1999).
Further investigation of the low-dose exposure effect
will define the conditions necessary to stimulate protec-
tive responses and the precise nature of such re-
sponses, including durability and specificity of protection
against antigenically and phenotypically diverse virus
stocks. Despite the absence of enhancement in the
present study, further investigations are required to ex-
clude this potentially important mechanism of mucosal
infection.
MATERIALS AND METHODS
Virus
SIVmac220 is a cell-free pool of virus derived from the
culture of spleen cells, taken from rhesus macaque 220,
167 days after infection with SIVmacJ5 (Polyanskaya et
al., 1997). Rhesus macaque 220 had been infected intra-
venously with 100 median monkey infectious doses
(MID50) of cell-free simian peripheral blood mononuclear
ell (PBMC)-grown SIVmacJ5, a pathogenic molecular
lone derived from SIVmac32H (Rud et al., 1994). The
irus pool SIVmac220 6/94 had a p27 antigen content of
.4 ng/ml and an in vitro titer of 104 TCID50/ml on C8166
cells.
SIV gp120 and antibody
Baculovirus expressed-SIV gp120 was produced and
purified to near homogeneity by monoclonal antibody
affinity chromatography as described by Doyle et al.
(1995). Rhesus anti-gp120 serum was obtained from
three macaques previously immunized with purified SIV
gp120. The serum pool had no virus infectivity-neutraliz-
ing activity. An immunoglobulin fraction was precipitated
with 50% ammonium sulfate and dialyzed against 0.01 M
Tris–phosphate buffer, pH 7.0. The IgG fraction was sep-
arated by DEAE cellulose ion-exchange chromatography
and purity demonstrated by immunoelectrophoresis
against anti-monkey IgG and anti-monkey whole serum
(Nordic Immunologicals, The Netherlands). Specificity for
gp120 was confirmed by ELISA.Immune complexes
Immune complexes of SIV gp120 and IgG were pre-
pared in antibody excess (gp120:IgG, 4:412 mg), at equiv-
lence (gp120:IgG, 8:200 mg), and in antigen excess
(gp120:IgG, 16:50 mg) and these were used in sequence
or the immunization of macaques. Antigen:antibody
quivalence was determined by preparing immune com-
lexes, followed by overnight incubation at room temper-
ture (total volume 0.2 ml). The complexes at different
atios were centrifuged for 5 min at 6000 rpm. The su-
ernatants were tested for free antibody on ELISA plates
oated with antigen and developed with rabbit anti-mon-
ey IgG–HRP conjugate (Sigma, Poole, UK). The first IgG
ilution that was negative for free antibodies was taken
s equivalence. The reason for using different antigen:
ntibody ratios for optimal uptake and presentation of
omplexed antigen was previously discussed (Manca et
l., 1991). For infectivity experiments an equal volume of
irus stock at a subinfectious dose (see below) was
ixed with an equal volume of IgG fraction at 1.85 mg/ml
approximately equivalent to 10% serum).
nimals
Juvenile Indian rhesus macaques were bred within the
nited Kingdom and housed according to the Home
ffice Code of Practice for the Housing and Care of
nimals Used in Scientific Procedure (1989). Primates
ere anesthetized with ketamine hydrochloride for all
rocedures requiring their removal from cages. Intrarec-
al inoculations with SIV were performed without trauma
sing a soft polypropylene 6FG catheter; each animal
eceived 3 ml of cell-free virus stock or SIV–IgG com-
lexes.
Animals were killed humanely by ketamine sedation
ollowed by intravenous injection of pentobarbitone (Eu-
hatal; Rhoˆne Me´rieux, Harlow, UK). Heparinized blood
was collected during terminal anesthesia, and spleen,
iliac lymph node, mesenteric lymph node, axillary lymph
node, sections of small intestine (jejunum/ileum), and
colon (including rectum) were collected immediately
post mortem.
Virus isolation, virus loads, PCR
Virus isolation was performed on PBMC from heparin-
ized blood. To determine cell-associated virus loads,
PBMC from each challenged animal were diluted from
106 to 4 3 105 and subsequently in fivefold steps to 130
cells and cocultivated in duplicate with C8166 human
T-cell line. Medium and cells were replenished every 3 to
4 days and the total culture volume was maintained at
approximately 15 ml. All cultures were maintained for 28
days or until cytopathic effect was apparent. Culture
results were confirmed by indirect immunofluoresence
staining for SIV antigen in acetone/methanol-fixed cells
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535LOCAL IMMUNITY AFTER LOW-DOSE MUCOSAL EXPOSURE TO SIVusing simian polyclonal anti-SIV serum. Fifty percent end
points were calculated using the Ka¨rber formula and the
results expressed as the number of virus-infected cells
per 106 PBMC. Viral isolation on C8166 cells was per-
ormed for PBMC and mononuclear cells from tissues
aken post mortem.
PCR for SIVmac proviral DNA was performed using
nv- and nef-specific primers on DNA extracted from
BMC and tissues (Kitchin et al., 1990a; Cranage et al.,
997). Quantitative competitive (QC) PCR for plasma RNA
as performed as described previously (ten Haaft et al.,
998). The assay had a dynamic range between 40 and
.6 3 107 RNA Eq/ml plasma.
Preparation of mononuclear cell suspensions from
blood and tissues
PBMC were isolated by Ficoll–Paque (Pharmacia, Mil-
ton Keynes, UK) density centrifugation from heparinized
blood and washed in culture medium RPMI 1640 (Gibco,
Paisley, UK) supplemented with L-glutamine (2 mM;
Gibco), penicillin (50 U/ml)/streptomycin (50 mg/ml;
ibco), and 10% heat-inactivated fetal bovine serum
FBS; Flow Laboratories, Oxon, UK). Splenic and lymph
ode MNC were obtained by teasing these tissues and
ashing cells in culture medium. Splenic MNC were
urified on Ficoll–Paque cushions. Intraepithelial lym-
hocytes (IEL) and lamina propria lymphocytes (LPL)
ere obtained by mechanical and enzymatic dissocia-
ion using modifications (see below) of a previously de-
cribed method (Bull and Bookman, 1977; James and
raeff, 1985). To obtain IEL, the small intestine (jejunum/
leum) and colon (including rectum) were washed in
anks’ balanced salt solution, without Ca21 and Mg21,
dissected into small fragments, incubated with 1 mM
dithiothreitol (Sigma) for 20 min at room temperature, and
vortexed on three occasions for 3 min as described by
Coue¨del-Courteille et al. (1997). Supernatants were
washed in a 25% Percoll solution (Pharmacia) and sep-
arated on 44/67% Percoll gradients for 20 min at 500 g,
and cells collected from the interface were washed and
used as IEL. Remaining tissue fragments were then
incubated at 37°C for 2 h in 0.75 mM EDTA (Sigma).
Epithelial removal with preservation of villus and lamina
propria structures was confirmed by histological exami-
nation. Tissue remaining after removal of IEL was cut
into smaller pieces and incubated at 37°C for 2 h in
culture medium with 90 IU/ml of collagenase (Sigma) and
0.02% DNase (Sigma). The supernatant was filtered
through a 100-mm nylon mesh, and the cells were sep-
arated by Ficoll–Paque gradient centrifugation and used
as LPL. More than 95% of the cells obtained from the gut
using this procedure were viable, as determined by
trypan blue exclusion. In some cases, digested tissue of
rectum was used (Bergmeier et al., 1998). The culture
medium was RPMI 1640 (Gibco) supplemented with 10%heat-inactivated fetal calf serum (FCS; Flow Laborato-
ries), 2 mM L-glutamine (Gibco), penicillin (100 U/ml)/
streptomycin (100 mg/ml) (Gibco), 80 mg/ml gentamicin
Sigma), 25 mM HEPES buffer (Sigma), 0.5 mg/ml ampho-
tericin B (Sigma), 0.05 mM 2-mercaptoethanol (Gibco),
and 5 IU/ml human recombinant interleukin 2 (IL-2; MRC
AIDS Reagent Project, ADP901).
ELISA
ELISA was performed using standard methods (Kitchin
et al., 1990b). Antigens were either recombinant SIV p27
or recombinant SIV gp120 or SIV gp 140 (MRC AIDS
Reagent Project, EVA643, EVA655, and EVA641, respec-
tively), or a detergent lysate of virus-infected C8166 cells
(whole SIV). Bound IgG antibody was detected using
rabbit anti-monkey IgG-AP or IgG-HRP conjugate
(Sigma). IgA antibody was detected by incubation with
rabbit anti-monkey IgA (Fc) (Nordic Immunologicals) fol-
lowed by goat anti-rabbit IgG-AP (Sigma).
Lymphoproliferative assay
Mononuclear cells from blood and tissues were as-
sayed in triplicate at 2 3 105 cells per well in 96-well
lates in the presence of SIV antigens (p27-GST and
aculovirus-produced gp120; MRC AIDS Reagent
roject, EVA655 and EVA643, respectively) at a concen-
ration range of 0.05–1.0 mg/well for 6–7 days or con-
anavalin A (1 mg/well; Sigma) for 3 days. [3H]Thymidine
Amersham, Buckinghamshire, UK) was added at 1 mCi/
well for 6 h, cells were harvested, and thymidine uptake
was measured using a b-counter. Proliferation was ex-
pressed as stimulation index (SI; mean [3H]thymidine
ncorporation of cells stimulated with antigen/mean in-
orporation in absence of stimulation). Unpaired Stu-
ent’s t test was used to determine significant differ-
nces between cell cultures without antigens and with
ifferent concentrations of SIV antigens.
TL assay
Fresh mononuclear cells from mucosa-associated
ymph nodes, spleen, and peripheral blood, isolated on
ensity gradients, were assessed for direct CTL activity.
arget cells were prepared from autologous Herpesvirus
apio-immortalized B-lymphoblastoid cell lines (B-LCL)
y overnight infection with 5 PFU/cell of recombinant
accinia viruses expressing either SIVnef (vv9011), SIV-
nv gp160 (vv9002), SIVgag (ARP274, ARP270, EVA261;
entralised Facility for AIDS Reagents, NIBSC, Potters
ar, UK), or influenza A protein PB2 (a kind gift from
rofessor F. Gotch, Chelsea and Westminster Hospital,
ondon). The following day, the cells were labeled with
50 mCi of Na2
51Cr (Amersham) for 1 h at 37°C. Effector
cells were combined with labeled target cells at effector-
to-target ratios ranging from 200:1 to 12.5:1 in 96-well
U-bottom plates. Following incubation at 37°C for 4 h,
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536 POLYANSKAYA ET AL.supernatants were collected with a harvester (Skatron,
Oslo, Norway) and release of chromium was measured
in a gamma counter. Total 51Cr incorporation was deter-
mined by incubation of targets with 2.5% (v/v) Triton X-100
and spontaneous release determined after incubation of
targets with medium alone. The tests were performed in
triplicate and the geometric mean was determined. CTL
activity was expressed as: % specific release 5 100 3
(experimental release, cpm 2 spontaneous release,
pm)/(total release, cpm 2 spontaneous release, cpm).
et SIV-specific activity was calculated by subtraction of
he % specific release from autologous targets infected
ith vaccinia virus expressing influenza PB2 from the %
pecific release from targets expressing SIV proteins.
numeration of antibody-secreting cells (ELISPOT
ssay)
ELISPOT assay was performed on frozen cells. Anti-
ody-secreting cells (ASC) were assayed in Microtitre
ultiscreen HA plates (Millipore UH, Watford, Herts, UK)
ith nitrocellulose bases and coated with SIV recombi-
ant p27 or gp140 (MRC AIDS Reagent Project, EVA655
nd EVA643, respectively), or keyhole limpet hemocyanin
KLH; Sigma) as a control, all at 10 mg/ml (Mo¨ller and
Borrebaeck, 1985; Bergmeier et al., 1998). An amplified
ELISPOT assay for the detection of macaque ASC was
used (Ericksson et al., 1992; Bergmeier et al., 1998). The
numbers of cells used in the antigen-specific ASC assay,
in triplicates, were: tissue-derived cells, 1 3 105, 5 3 104,
nd 104 cells per well; PBMC, 5, 2, and 1 3 105 cells per
well. The cells were incubated for 16 h at 37°C in 5%
CO2. Glutaraldehyde-inactivated and -washed plates
ere incubated with biotinylated Fc-specific goat anti-
uman IgG (Tago Immunologicals, Camarillo, CA) or bi-
tinylated Fc-specific goat anti-monkey IgA (Nordic Im-
unologicals) (Bergmeier et al., 1998), then treated with
vidin-conjugated peroxidase (Sigma), followed by bio-
inylated rabbit anti-peroxidase (Jackson Immunore-
earch Laboratories, West Grove, PA). The reaction was
mplified by repeating the incubation with avidin-conju-
ated peroxidase. Plates were developed with AEC/hy-
rogen peroxide (Sigma). The spots were enumerated
nder low magnification (320) with a binocular micro-
cope. The results were expressed as the means 6 SEM
f the number of spots per 1 3 106 cells. Total immuno-
globulin-secreting cells were also assayed as a positive
control (data not shown).
ACKNOWLEDGMENTS
This work was supported by the U.K. Department of Health and
European Vaccine against AIDS (Programme EVA; Contract No. BMH4
97/2515). We are grateful to Dr. Harvey Holmes (AIDS Reagent Repos-
itory, NIBSC, UK) and Dr. Ian Jones (IOV, Oxford) for the provision of
many of the reagents and to Kate Pratt for technical help.REFERENCES
Baba, T. W., Liska, V., Hofmann-Lehmann, R., Vlasak, J., Xu, W., Ayehu-
nie, S., Cavacini, L. A., Posner, M. R., Katinger, H., Stiegler, G.,
Bernacky, B. J., Rizvi, T., Schmidt, R., Hill, L. R., Keeling, M. E., Lu, Y.,
Wright, J. E., Chou, T.-C., and Ruprecht, R. M. (2000). Human neutral-
izing monoclonal antibodies of the IgG1 subtype protect against
mucosal simian-human immunodeficiency virus infection. Nat. Med.
6, 200–206.
Bergmeier, L. A., Mitchell, E. A., Hall, G., Cranage, M. P., Cook, N.,
Dennis, M., and Lehner, T. (1998). Antibody secreting cells to SIV
antigens in lymphoid and mucosal tissues of immunized macaques.
AIDS 12, 1139–1147.
Boyer, V., Desgranges, C., Trabaud, M.-A., Fischer, E., and Kazatchkine,
M. D. (1991). Complement mediates human immunodeficiency virus
type 1 infection of a human T cell line in a CD4- and antibody-
independent fashion. J. Exp. Med. 173, 1151–1158.
Bull, D. M., and Bookman, M. A. (1977). Isolation and functional char-
acterization of human intestinal mucosal lymphoid cells. J. Clin.
Invest. 59, 966–974.
Clerici, M. (1992). Cell-mediated immune response to human immuno-
deficiency virus (HIV) type 1 in seronegative homosexual men with
recent sexual exposure to HIV-1. J. Infect. Dis. 165, 1012–1019.
Clerici, M., Clark, E. A., Polacino, P., Axberg, I., Kuller, L., Casey, N. I.,
Morton, W. R., Shearer, G. M., and Benveniste, R. E. (1994). T-cell
proliferation to subinfectious SIV correlates with lack of infection
after challenge of macaques. AIDS 8, 1391–1395.
Code of Practice for the Housing and Care of Animals Used in Scientific
Procedures. (1989). Home Office Publication 107. HMSO, London.
Coue¨del-Courteille, A., Le Grand, R., Tulliez, M., Guillet, J.-G., and Venet,
A. (1997). Direct ex vivo simian immunodeficiency virus (SIV)-specific
cytotoxic activity detected from small intestine intraepithelial lympho-
cytes of SIV-infected macaques at an advanced stage of infection.
J. Virol. 71, 1052–1057.
Cranage, M. P., Baskerville, A., Ashworth, L. A. E., Dennis, M., Cook, N.,
Cook, R., Sharpe, S. A., Rose, J., Kitchin, P., and Greenaway, P. J.
(1992). Mucosal infection and vaccine studies with macaque SIV.
Vaccine Res. 1, 311–318.
Cranage, M. P., Whatmore, A. M., Sharpe, S. A., Cook, N., Polyanskaya,
N., Leech, S., Smith, J. D., Rud, E. W., Dennis, M. J., and Hall, G. A.
(1997). Macaques infected with live attenuated SIVmac are protected
against superinfection via the rectal mucosa. Virology 229, 143–154.
Dittmer, U., Stahl-Hennig, C., Coulibaly, C., Nisslein, T., Lu¨ke, W., Fuchs,
D., Bodemer, W., Petry, H., and Hunsmann, G. (1995). Repeated
exposure of rhesus macaques to low doses of simian immunodefi-
ciency virus (SIV) did not protect them against the consequences of
a high-dose SIV challenge. J. Gen. Virol. 76, 1307–1315.
Doyle, C. B., Bhattacharyya, U., Kent, K. A., Stott, J. E., and Jones, I. M.
(1995). Regions required for CD4 binding in the external glycoprotein
gp120 of simian immunodeficiency virus. J. Virol. 69, 1256–1260.
Eriksson, K., Nordstro¨m, I., Horal, P., Jeansson, S., Svennerholm, B.,
Vahlne, A., Holmgren, J., and Czerkinsky, C. (1992). Amplified
ELISPOT assay for the detection of HIV-specific antibody-secreting
cells in subhuman primates. J. Immunol. Methods 153, 107–113.
Homsy, J., Meyer, M., Tateno, M., Clarkson, S., and Levy, J. A. (1989). The
Fc and not CD4 receptor mediates antibody enhancement of HIV
infection in human cells. Science 244, 1357–1360.
Hussain, L. A., Kelly, C. G., Hecht, E.-M., Felloes, R., Jourdan, M., and
Lehner, T. (1991). The expression of Fc receptors for immunoglobu-
lins G in human rectal epithelium. AIDS 5, 1089–1094.
Hussain, L. A., and Lehner, T. (1995). Comparative investigation of
Langerhans’ cells and potential receptors for HIV in oral, genitouri-
nary and rectal epithelia. Immunology 85, 475–484.
James, S. P., and Graeff, A. S. (1985). Spontaneous and lymphokine
induced cytotoxic activity of monkey intestinal lymphocytes. Cell
Immunol. 93, 387–397.
Kaul, R., Trabattoni, D., Bwayo, J. J., Arienti, D., Zagliani, A., Mwangi,
KK
L
M
M
R
R
R
R
R
S
S
S
S
S
S
537LOCAL IMMUNITY AFTER LOW-DOSE MUCOSAL EXPOSURE TO SIVF. M., Kariuki, C., Ngugi, E. N., MacDonald, K. S., Ball, T. B., Clerici, M.,
and Plummer, F. A. (1999). HIV-1-specific mucosal IgA in a cohort of
HIV-1-resistant Kenian sex workers. AIDS 13, 23–29.
itchin, P. A., Almond, N., Szotyori, Z., Fromholc, C. E., McAlpine, L.,
Silvera, P., Stott, E. J., Cranage, M., Baskerville, A., and Schild, G.
(1990a). The use of the polymerase chain reaction for the detection
of simian immunodeficiency virus in experimental infected ma-
caques. J. Virol. Methods 28, 85–100.
itchin, P. A., Cranage, M. P., Almond, N., Barnard, A., Baskerville, A.,
Corcoran, T., Fromholc, C., Greenaway, P., Grief, C., Jenkins, A., Kent,
K., Ling, C., Mahon, B., Mills, K., Page, M., Silvera, P., Szotyori, Z.,
Taffs, F., and Stott, E. J. (1990b). Titration of SIVmac251 (32H isolate)
in cynomolgus macaques for use as a challenge in vaccination
studies. In “Animal Models in AIDS” (H. Schellekens and M. C.
Horzinek, Eds.), pp. 115–129. Elsevier Science Publishers B.V., Am-
sterdam.
anglade-Demoyen, P. N., Ngo-Giang-Huong, F. F., and Oksenhendler,
E. (1994). HIV nef-specific cytotoxic T lymphocytes in noninfected
heterosexual contact of HIV-infected patients. J. Clin. Invest. 93,
1293–1297.
Lehner, T., Bergmeier, L., Wang, Y., Tao, L., and Mitchel, E. (1999). A
rational basis for mucosal vaccination against HIV infection. Immu-
nol. Rev. 170, 183–196.
Lehner, T., Bergmeier, L. A., Tao, L., Panagiotidi, C., Klavinskis, L. S.,
Hussain, L., Ward, R. G., Meyers, N., Adams, S. E., Gearing, A. J. H.,
and Brookes, R. (1994). Targeted lymph node immunization with
simian immunodeficiency virus p27 antigen to elicit genital, rectal
and urinary immune responses in nonhuman primates. J. Immunol.
153, 1858–1868.
Lehner, T., Wang, Y., Cranage, M., Bergmeier, L. A., Mitchell, E., Tao, L.,
Hall, G., Dennis, M., Cook, N., Brooks, R., Klavinskis, L., Jones, I.,
Doyle, C., and Ward, R. (1996). Protective mucosal immunity elicited
by targeted iliac lymph node immunization with a subunit SIV enve-
lope and core vaccine in macaques. Nat. Med. 2, 767–775.
Manca, F., Fenoglio, D., Li Pira, G., Kunkl, A., and Celada, F. (1991). Effect
of antigen antibody ratio on macrophage uptake, processing and
presentation to T cells of antigen complexed with polyclonal anti-
bodies. J. Exp. Med. 173, 37–48.
Mascola, J. R., Stiegler, G., VanCott, T. C., Katinger, H., Carpenter, C. B.,
Hanson, C. E., Beary, H., Hayes, D., Frankel, S., Birx, D. L., and Lewis,
M. G. (2000). Protection of macaques against vaginal transmission of
a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutral-
izing antibodies. Nat. Med. 6, 207–210.
azzoli, S., Trabattoni, D., Caputo, S. L., Piconi, S., Ble´, C., Meacci, F.,
Ruzzante, S., Salvi, A., Semplici, F., Lounghi, R., Fusi, M. L., Tofani, N.,
Biasin, M., Villa, M. L., Mazzotta, F., and Clerici, M. (1997). HIV-
specific mucosal and cellular immunity in HIV-seronegative partners
of HIV-seropositive individuals. Nat. Med. 3, 1250–1257.
cChesney, M. B., Collins, J. R., Lu, D., Lu, X., Torten, J., Ashley, R. L.,
Cloyd, M. W., and Miller, C. J. (1998). Occult systemic infection and
persistent simian immunodeficiency virus (SIV)-specific CD41-T-cell
proliferative responses in rhesus macaques that were transiently
viremic after intravaginal inoculation of SIV. J. Virol. 72, 10029–10035.
Mo¨ller, S. A., and Borrebaeck, C. A. K. (1985). A filter immuno-plaque
assay for the detection of antibody-secreting cells in vitro. J. Immu-
nol. Methods 79, 195–204.
Montefiory, D. C., Robinson, W. E., Jr., Hirsch, V., Modliszewski, A.,
Mitchell, W., and Johnson, P. R. (1990). Antibody-dependent enhance-
ment of simian immunodeficiency virus (SIV) infection in vitro by
plasma from SIV-infected rhesus macaques. J. Virol. 64, 113–119.
Murphey-Corb, M., Wilson, L. A., Trichel, A. M., Roberts, D. E., Xu, K.,
Ohkawa, S., Woodson, B., Bohm, R., and Blanchard, J. (1999). Selec-
tive induction of protective MHC class I-restricted CTL in the intes-
tinal lamina propria of rhesus monkeys by transient SIV infection of
the colonic mucosa. J. Immunol. 162, 540–549.Osterhaus, A. D. M. E., Tijhaar, E., Huisman, R., Huisman, W., Darby,
I. H., Francis, M. J., Rimmelzwaan, G. F., and Siebelink, K. H. J. (1996).Accelerated viremia in cats vaccinated with recombinant vaccinia
virus expressing envelope glycoprotein of feline immunodeficiency
virus. AIDS Res. Hum. Retroviruses 12, 437–441.
Pauza, C. D., Emau, P., Salvato, M. S., Triverdi, P., MacKenzie, D.,
Malkovsky, M., Uno, H., and Schultz, K. T. (1993). Pathogenesis of
SIVmac251 after atraumatic inoculation of the rectal mucosa in rhesus
monkeys. J. Med. Primatol. 22, 154–161.
Polyanskaya, N., Sharpe, S., Cook, N., Leech, S., Banks, J., Dennis, M.,
Hall, G., Stott, J., and Cranage, M. (1997). Anti-MHC histocompatibility
complex antibody responses to simian B cells do not protect ma-
caques against SIVmac infection. AIDS Res. Hum. Retroviruses 13,
923–931.
Putkonen, P., Ma¨kitalo, B., Bo¨ttiger, D., Biberfeld, G., and Thorstensson,
R. (1997). Protection of human immunodeficiency virus type 2-ex-
posed seronegative macaques from mucosal simian immunodefi-
ciency virus transmission. J. Virol. 71, 4981–4984.
obinson, W. E., Jr., Kawamura, T., Lake, D., Masuho, Y., Mitchell, W. M.,
and Hersch, E. M. (1990). Antibodies to the primary immunodominant
domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein
gp41 enhance HIV-1 infection in vitro. J. Virol. 64, 5301–5305.
owland-Jones, S. L., Dong, T., Fowke, K. R., Kimani, J., Krausa, P.,
Newell, H., Blanchard, T., Ariyoshi, K., Oyugi, J., Ngugi, E., Bwayo, J.,
MacDonald, K. S., McMichael, A. J., and Plummer, F. A. (1998).
Cytotoxic T cell responses to multiple conserved HIV epitopes in
HIV-resistant prostitutes in Nairobi. J. Clin. Invest. 102, 1758–1765.
owland-Jones, S. L., Nixon, D. F., Aldhous, M. C., Gotch, F., Ariyosi, K.,
Hallam, N., Kroll, J. S., Froebel, K., and McMichael, A. (1993). HIV-
specific cytotoxic T-cell activity in an HIV-exposed but uninfected
infant. Lancet 341, 860–861.
owland-Jones, S. L., Sutton, J., Ariyoshi, K., Dong, T., Gotch, F., Mc-
Adam, S., Whitby, D., Sabally, S., Gallimore, A., Corrah, T., Takiguchi,
M., Schultz, T., McMichael, A., and Whittle, H. (1995). HIV-specific
cytotoxiv T cells in HIV-exposed but uninfected Gambian women.
Nat. Med. 1, 59–64.
ud, E. W., Cranage, M., Yon, J., Quirk, J., Ogilvie, L., Cook, N., Webster,
S., Dennis, M., and Clarke, B. E. (1994). Molecular and biological
characterization of simian immunodeficiency virus macaque strain
32H proviral clones containing nef size variants. J. Gen. Virol. 75,
529–543.
alvato, M. S., Emau, P., Malkovsky, M., Schultz, K. T., Johnson, E., and
Pauza, C. D. (1994). Cellular immune responses in rhesus macaques
infected rectally with low dose simian immunodeficiency virus.
J. Med. Primatol. 23, 125–130.
attentau, Q. J., and Moore, J. P. (1995). Human immunodeficiency virus
type 1 neutralization is determined by epitope exposure on the gp120
oligomer. J. Exp. Med. 182, 185–196.
chutten, M., Andeweg, A. C., Bosch, M. L., and Osterhaus, A. D. M. E.
(1994). Enhancement of infectivity of a non-syncytium inducing HIV-1
by sCD4 and by human antibodies that neutralize syncytium inducing
HIV-1. Scand. J. Immunol. 41, 18–22.
hearer, G. M., and Clerici, M. (1996). Protective immunity against HIV
infection: Has nature done the experiment for us? Immunol. Today 17,
21–24.
iebelink, K. H. J., Tijhaar, E., Huisman, R. C., Huisman, W., de Ronde,
A., Darby, I. H., Francis, M. J., Rimmelzwaan, G. F., and Osterhaus,
A. D. M. E. (1995). Enhancement of feline immunodeficiency virus
infection after immunisation with envelope glycoprotein subunit vac-
cines. J. Virol. 69, 3704–3711.
tranford, S. A., Skurnic, J., Louria, D., Osmond, D., Chang, S.-Y., Shinsky,
J., Ferrari, G., Weinhold, K., Lindquist, C., and Levy, J. A. (1999). Lack
of infection in HIV-exposed individuals is associated with a strong
CD81 cell noncytotoxic anti-HIV response. Proc. Natl. Acad. Sci. USA
96, 1030–1035.
Takeda, A., and Ennis, F. A. (1990). FcR-mediated enhancement of HIV-1
infection by antibody. AIDS Res. Hum. Retroviruses 6, 999–1004.
Takeda, A.,Tuazon, C. U., and Ennis, F. A. (1988). Antibody-enhanced
tT
T
538 POLYANSKAYA ET AL.infection by HIV-1 via Fc receptor-mediated entry. Science 242,
580–583.
en Haaft, P., Verstrepen, B., U¨berla, K., Rosenwirth, B., and Heeney, J.
(1998). A pathogenic threshold of virus load defined in simian immu-
nodeficiency virus- or simian-human immunodeficiency virus-in-
fected macaques. J. Virol. 72, 10281–10285.
rishmann, H., Davis, D., and Lachmann, P. J. (1995). Lymphocytotropic
strains of HIV type 1 when complexed with enchancing antibodies
can infect macrophages via FcgRIII, independently of CD4. AIDS Res.
Hum. Retroviruses 11, 343–352.
rivedi, P., Horejsh, D., Hinds, S. B., Hinds II, P. W., Wu, M. S., Salvato,
M. S.,and Pauza, C. D. (1996). Intrarectal transmission of simian
immunodeficiency virus in rhesus macaques: Selective amplification
and host responses to transient or persistent viremia. J. Virol. 70,
6876–6883.Van Rompay, K., Marthas, M., Lifson, J., Berardi, C., Vasquez, G., Agatep,
E., Dehqanzada, Z., Cundy, K., Bischofberger, N., and Pedersen, N.(1998). Administration of 9-{2-(phosphonomethoxy)-propyl}adenine
(PMPA) for prevention of perinatal simian immunodeficiency virus
infection in rhesus macaques. AIDS Res. Hum. Retroviruses 14,
761–773.
Veazey, R. S., DeMaria, M. A., Chalifoux, L. V., Shvetz, D. E., Pauley, D. R.,
Knight, H. L., Rosenzweig, M., Johnson, R. P., Desrosiers, R. C., and
Lackner, A. A. (1998). Gastrointestinal tract as a major site of CD41
T cell depletion and viral replication in SIV infection. Science 280,
427–431.
Witkin, S. S., Shahani, S. K., Gupta, S., Good, R. A., and Day, N. K. (1980).
Demonstration of IgG Fc receptors on spermatozoa and their utili-
zation for the detection of circulating immune complexes in human
serum. Clin. Exp. Immunol. 41, 441–452.
Zhou, M.-J., Todd III, R. F., Van de Winkel, J. G. J., and Petty, H. R. (1993).
Cocapping of the leukoadhesion molecules comlement receptor type
3 and lymphocyte function-associated antigen-1 with Fcg receptor III
on human neutrophils. J. Immunol. 150, 3030–3041.
